Behcet's disease (BD) is a chronic relapsing multisystem disease characterized by oral ulceration, genital ulceration and ocular lesions. Gastrointestinal involvement is rare, often difficult to treat and associated with a high mortality rate. We treated a 47-year-old Korean man with BD who had a recurrent intestinal ulcer with tumor necrosis factor alpha antibody (infliximab); he initially underwent right hemicolectomy due to uncontrolled intestinal bleeding. For patients with intestinal BD who fail to respond to conventional treatment, infliximab may be a safe and effective new therapeutic option.
Tumor Necrosis Factor-alpha/*therapeutic use ; *Treatment Outcome ; Remission Induction ; Middle Aged ; Male ; Humans ; Gastrointestinal Diseases/*drug therapy/etiology/surgery ; Gastrointestinal Agents/*therapeutic use ; Disease Progression ; Colectomy ; Behcet Syndrome/*drug therapy/physiopathology/surgery ; Antibodies, Monoclonal/*therapeutic use